Marketing-authorisation holder · United States
Harrow Eye
18 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
18 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BYQLOVI0.05% · Suspension/drops | Clobetasol | United States | Marketed | 2024 |
| ECONOPRED0.125% · Suspension/drops | Prednisolone | United States | Not marketed | 1973 |
| FLAREX0.1% · Suspension/drops | Fluorometholone | United States | Marketed | 1986 |
| IHEEZO3% · GEL | Chloroprocaine | United States | Marketed | 2022 |
| ILEVRO0.3% · Suspension/drops | Nepafenac | United States | Marketed | 2012 |
| IOPIDINE0.5% base | 1% base · Solution/drops | Apraclonidine | United States | Marketed | 1987 |
| MAXIDEX0.1% · Suspension/drops | Dexamethasone | United States | Marketed | 1962 |
| MOXEZA0.5% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution/drops | Moxifloxacin | United States | Not marketed | 2010 |
| NATACYN5% · Suspension | Natamycin | United States | Marketed | 1978 |
| NEVANAC0.1% · Suspension/drops | Nepafenac | United States | Marketed | 2005 |
| TOBRADEX ST0.05%; 0.3% · Suspension/drops | Dexamethasone, Tobramycin | United States | Marketed | 2009 |
| TOBRASONE0.1%; 0.3% · Suspension/drops | Fluorometholone, Tobramycin | United States | Not marketed | 1989 |
| TRIESENCE40mg/ml (40mg/ml) · Injectable | Triamcinolone | United States | Marketed | 2007 |
| VERKAZIA0.1% · Emulsion | Ciclosporin | United States | Marketed | 2021 |
| VEVYE0.1% · Solution | Ciclosporin | United States | Marketed | 2023 |
| VEXOL1% · Suspension/drops | Rimexolone | United States | Not marketed | 1994 |
| VIGAMOX0.5% base · Solution/drops | Moxifloxacin | United States | Marketed | 2003 |
| ZERVIATE0.24% base · Solution/drops | Cetirizine | United States | Marketed | 2017 |